
COVID-19 Outpatient TherapeuticsClinical Decision Aid for Ages 12+ years

Adult or pediatric patient (ages 12 and older weighing at least 40 kg) with mild to moderate COVID-19 and at high risk for progression to severe disease



Consider one of the following therapeutics, if available, feasible, and clinically appropriate¹:

Paxlovid² within 5 days of symptom onset If patient does not have severe renal impairment (eGFR <30mL/min) OR severe hepatic impairment (Child-Pugh Class C)

- eGFR ≥ 60 mL/min: 300 mg nirmatrelvir taken with 100 mg ritonavir twice daily for 5 days
- eGFR ≥ 30 to < 60: 150 mg nirmatrelvir taken together with 100 mg ritonavir twice daily for 5 days
- Evaluate concomitant use of CYP3A inducers and medications with high dependency on CYP3A for clearance as these may be contraindicated^{2,3}

OR

Veklury (remdesivir)⁴ 200 mg IV x 1 dose on Day 1, 100 mg IV x 1 on Days 2–3 begun **ASAP within 7 days of symptom onset**

If Paxlovid and Veklury (remdesivir) are not available, feasible or clinically appropriate, consider one of the following therapeutics:

bebtelovimab⁵ ASAP within 7 days of symptom onset 175 mg single IV injection

OR

Lagevrio (molnupiravir)⁶ If patient age 18 or older AND possibility of pregnancy, if applicable, ruled out:

800 mg by mouth every 12h for 5 days begun **ASAP within 5 days of symptom onset**

Prescribers must review and comply with the mandatory requirements outlined in the **Lagevrio** (molnupiravir) EUA⁶

References:

1 NIH's COVID-19 Treatment Guidelines Therapeutic Management of Nonhospitalized Adults With COVID-19. https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/

VIH's COVID-19 Treatment Guidelines Panel: Ritonavir-Boosted Nirmatrelvir (Paxlovid), https://www.covid19treatmentquidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir-paxlovid-/

eklury (remdesivir) Prescribing Information. https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury pi.pdf

Bebtelovimab EUA, https://www.fda.gov/media/156152/download

⁶ Lagevrio EUA. https://www.fda.gov/media/15054/download





COVID-19 Outpatient Therapeutics

Clinical Decision Aid for Ages 28 days to less than 12 years

Pediatric patient (28 days of age to less than 12 years, weighing at least 3 kg to less than 40 kg) with mild to moderate COVID-19 and at high risk for progression to severe disease

